Compare ELOG & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELOG | NOTV |
|---|---|---|
| Founded | 2006 | 1974 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.3M | 23.0M |
| IPO Year | 2025 | 1997 |
| Metric | ELOG | NOTV |
|---|---|---|
| Price | $1.15 | $0.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 1.9M | 549.0K |
| Earning Date | 02-10-2026 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.27 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | $45,962,309.00 | ★ $513,024,000.00 |
| Revenue This Year | N/A | $6.49 |
| Revenue Next Year | N/A | $4.95 |
| P/E Ratio | $7.22 | ★ N/A |
| Revenue Growth | ★ 10.64 | 4.54 |
| 52 Week Low | $0.88 | $0.47 |
| 52 Week High | $3.60 | $5.67 |
| Indicator | ELOG | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 31.07 |
| Support Level | N/A | $0.47 |
| Resistance Level | N/A | $0.69 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 25.83 |
Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products. Its segments are Transportation services and Warehouse subleasing services. The group generates the majority of its revenue from Transportation services.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.